IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc. (IDXX) Financial Performance & Income Statement Overview
Explore the financials of IDEXX Laboratories, Inc. (IDXX), including yearly and quarterly data on income, cash flow, and balance sheets.
IDEXX Laboratories, Inc. (IDXX) Income Statement & Financial Overview
View the income breakdown for IDEXX Laboratories, Inc. IDXX across both annual and quarterly reports.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $954.29M | $975.54M | $1.004B | $964.10M |
| Cost of Revenue | $383.63M | $379.50M | $382.70M | $371.02M |
| Gross Profit | $570.66M | $596.04M | $620.88M | $593.07M |
| Gross Profit Ratio | $0.60 | $0.61 | $0.62 | $0.62 |
| R&D Expenses | $57.73M | $53.98M | $55.45M | $52.63M |
| SG&A Expenses | $251.25M | $238.17M | $299.91M | $241.48M |
| Operating Expenses | $308.97M | $292.15M | $355.36M | $294.11M |
| Total Costs & Expenses | $692.60M | $671.65M | $738.06M | $665.14M |
| Interest Income | $2.20M | $2.71M | $3.35M | $4.43M |
| Interest Expense | $7.50M | $7.70M | $8.10M | $7.91M |
| Depreciation & Amortization | $33.71M | $34.13M | $32.19M | $29.90M |
| EBITDA | $297.59M | $342.00M | $300.73M | $334.55M |
| EBITDA Ratio | $0.31 | $0.35 | $0.30 | $0.35 |
| Operating Income | $261.69M | $303.89M | $265.52M | $298.96M |
| Operating Income Ratio | $0.27 | $0.31 | $0.26 | $0.31 |
| Other Income/Expenses (Net) | -$5.30M | -$4.98M | -$4.75M | -$3.48M |
| Income Before Tax | $256.39M | $298.91M | $259.06M | $295.48M |
| Income Before Tax Ratio | $0.27 | $0.31 | $0.26 | $0.31 |
| Income Tax Expense | $40.24M | $66.07M | $55.76M | $59.90M |
| Net Income | $216.15M | $232.84M | $203.30M | $235.58M |
| Net Income Ratio | $0.23 | $0.24 | $0.20 | $0.24 |
| EPS | $2.63 | $2.83 | $2.46 | $2.84 |
| Diluted EPS | $2.62 | $2.80 | $2.44 | $2.81 |
| Weighted Avg Shares Outstanding | $82.30M | $82.30M | $82.63M | $83.10M |
| Weighted Avg Shares Outstanding (Diluted) | $82.54M | $83.06M | $83.39M | $83.96M |
The company's financials show resilient growth, with revenue advancing from $964.10M in Q1 2024 to $954.29M in Q4 2024. Gross profit remained healthy with margins at 60% in Q4 2024 compared to 62% in Q1 2024. Operating income hit $261.69M last quarter, sustaining a consistent 27% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $297.59M. Net income dropped to $216.15M, while earnings per share reached $2.63. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan